{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:44:54Z","timestamp":1772833494302,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["204524"],"award-info":[{"award-number":["204524"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.resinv.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:22:48Z","timestamp":1747732968000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and effectiveness of mepolizumab for patients with bronchial asthma in routine clinical practice in Japan \u2014 final report of special drug use investigation"],"prefix":"10.1016","volume":"63","author":[{"given":"Eriko","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1759-323X","authenticated-orcid":false,"given":"Hironobu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Komatsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.05.003_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-023-02475-6","article-title":"Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"24","author":"Wang","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.05.003_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1183\/23120541.00122-2024","article-title":"Epidemiology of patients with severe asthma in Japan: a nationwide descriptive study","volume":"10","author":"Kimura","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2025.05.003_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinthera.2019.08.015","article-title":"The prevalence, characteristics, and patient burden of severe asthma determined by using a Japan health care claims database","volume":"41","author":"Sato","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib6","first-page":"403","article-title":"Post\u2013marketing surveillance of mepolizumab use in patients with eosinophilic granulomatosis with polyangiitis in Japan: interim analysis","volume":"42","author":"Fujii","year":"2021","journal-title":"Ther Res"},{"key":"10.1016\/j.resinv.2025.05.003_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41533-019-0128-8","article-title":"A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan","volume":"29","author":"Inoue","year":"2019","journal-title":"NPJ Prim Care Respir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.resinv.2025.05.003_bib8","first-page":"1","article-title":"The Global Asthma Report 2022","volume":"26","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2025.05.003_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","article-title":"Executive summary: Japanese guidelines for adult asthma (JGL) 2021","volume":"72","author":"Niimi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.05.003_bib11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.resinv.2025.05.003_bib12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/cea.14489","article-title":"Role of IL-5 in asthma and airway remodelling","volume":"54","author":"Abujabal","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2025.05.003_bib13","first-page":"619","article-title":"Mepolizumab (Nucala) for severe eosinophilic asthma","volume":"41","author":"Choy","year":"2016","journal-title":"P T"},{"key":"10.1016\/j.resinv.2025.05.003_bib14","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.05.003_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.resinv.2025.05.003_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/02770903.2019.1658208","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma","volume":"58","author":"Pertzov","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.resinv.2025.05.003_bib17","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review","volume":"59","author":"Israel","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.resinv.2025.05.003_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618808490","article-title":"Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience","volume":"12","author":"Emma","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2025.05.003_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.003_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.05.003_bib23","first-page":"405","article-title":"Evaluation of long\u2012term safety and effectiveness of mepolizumab (genetical recombination)in patients with bronchial asthma in routine clinical practice","volume":"44","author":"Tsuboi","year":"2023","journal-title":"Ther Res"},{"key":"10.1016\/j.resinv.2025.05.003_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.05.003_bib26","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.05.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: The COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.alit.2024.12.005","article-title":"Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: improvements in rhinosinusitis imaging (J-Real-Mepo)","author":"Nagase","year":"2025","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.05.003_bib30","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1007\/s12325-024-02967-x","article-title":"Real-world effectiveness of mepolizumab in severe asthma: results from the multi-country, self-controlled Nucala effectiveness study (NEST)","volume":"41","author":"Al-Lehebi","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/resp.14729","article-title":"Asthma\u2010related death trends and biologics use for severe asthma in the super\u2010aged society of Japan","volume":"29","author":"Kan\u2010O","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2025.05.003_bib32","series-title":"Efficacy and safety study of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma","year":"2018"},{"key":"10.1016\/j.resinv.2025.05.003_bib33","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/02770903.2021.1971700","article-title":"Factors leading to discontinuation of biologic therapy in patients with severe asthma","volume":"59","author":"Silver","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.resinv.2025.05.003_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.rmed.2018.06.021","article-title":"Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan","volume":"141","author":"Adachi","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.05.003_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.05.003_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JAA.S432695","article-title":"Real-world safety and effectiveness of benralizumab in Japanese patients with severe asthma: a multicenter prospective observational study","author":"Yamaguchi","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.05.003_bib37","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1007\/s12325-023-02660-5","article-title":"Relationship between asthma control status and health-related quality of life in Japan: a cross-sectional mixed-methods study","volume":"40","author":"Nagase","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.003_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241308406","article-title":"A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT)","volume":"19","author":"Cheng","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2025.05.003_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12063","article-title":"Effectiveness of mepolizumab in severe asthma in Japan: a real\u2010world study using claims data","volume":"11","author":"Nagase","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.resinv.2025.05.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102130","article-title":"Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: a real-world database study in Japan","volume":"75","author":"Nagase","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2025.05.003_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaip.2017.05.010","article-title":"Validity of the asthma control test questionnaire among smoking asthmatics","volume":"6","author":"Soler","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.05.003_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.05.003_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2169\/internalmedicine.9339-22","article-title":"Measurement of blood eosinophils in asthma and chronic obstructive pulmonary disease","volume":"62","author":"Hirano","year":"2023","journal-title":"Intern Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253452500067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253452500067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:50:38Z","timestamp":1749599438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221253452500067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S221253452500067X"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.003","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and effectiveness of mepolizumab for patients with bronchial asthma in routine clinical practice in Japan \u2014 final report of special drug use investigation","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}